Braeburn Pharmaceuticals and Camurus present positive data from opioid use disorder clinical studies
27 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Phase 3 study was designed to demonstrate the safety and efficacy of CAM2038 as compared to the sublingual buprenorphine in treating opioid use disorder...